Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

The purpose of this study is to learn whether clinical response (the amount a tumor shrinks based on imaging or tumor measurements obtained by physical exam) predicts pathologic response (the amount of tumor remaining when surgery is performed) in participants with breast cancer who are receiving chemotherapy prior to surgery.

Trial Details

NCT ID

NCT05020860

Phase

PHASE2

Sponsor

Baylor Breast Care Center

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Paclitaxel
Carboplatin
Trastuzumab
Pertuzumab
Doxorubicin
Cyclophosphamide

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327
Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

At least 18 years of age, and legally able to provide informed consent. Both men and women are eligible.
Histologically confirmed, invasive breast cancer. Tumor may be triple negative (as defined by ASCO-CAP guidelines), HER2-positive (as defined by AS…
To be considered "high risk," at least 2 of the following criteria must be met: 1) histologic grade 3; 2) patient age 50 or less; 3) ER Allred scor…
Tumors must be at least 2 cm by clinical exam or ultrasound

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →